Home » Stocks » LMNL

Liminal BioSciences Inc. (LMNL)

Stock Price: $4.15 USD -0.08 (-1.89%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $4.02 -0.13 (-3.13%) May 13, 4:48 PM
Market Cap 129.63M
Revenue (ttm) 2.60M
Net Income (ttm) -93.80M
Shares Out 29.94M
EPS (ttm) -3.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $4.15
Previous Close $4.23
Change ($) -0.08
Change (%) -1.89%
Day's Open 4.26
Day's Range 3.53 - 4.40
Day's Volume 755,155
52-Week Range 3.51 - 31.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Liminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

Liminal BioSciences Inc. (LMNL) delivered earnings and revenue surprises of -8.77% and 52.73%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Initiated Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras OXER1 Antagonist Preclinical R&D Program Acquired Changes to Board of Directors & Executive Team US$30M in gross proceeds from a pr...

1 month ago - PRNewsWire

Liminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other stocks mentioned: BJ, BLCM, QFIN, VCNX, VIVO
4 months ago - Zacks Investment Research

LAVAL, QC, and CAMBRIDGE, England, Dec. 15, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announ...

4 months ago - PRNewsWire

Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

LAVAL, QC and CAMBRIDGE, England, Nov. 13, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced tha...

6 months ago - PRNewsWire

LAVAL, QC and CAMBRIDGE, England, Nov. 10, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announc...

6 months ago - PRNewsWire

PDUFA date extended by FDA from March 5, 2021 to June 5, 2021 Earnings call moved forward to Wednesday November 11th LAVAL, QC, and CAMBRIDGE, England, Nov. 8, 2020 /PRNewswire/ - Liminal BioSciences In...

6 months ago - PRNewsWire

LAVAL, QC and CAMBRIDGE, England, Nov. 6, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announce...

6 months ago - PRNewsWire

LAVAL, QC and CAMBRIDGE, England, Nov. 5, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announce...

6 months ago - PRNewsWire

- FDA assigns PDUFA target action date of March 5, 2021 LAVAL, QC and CAMBRIDGE, England, Sept. 21, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), ...

7 months ago - PRNewsWire

The pandemic highlights how far medical science has come. It also highlights how exciting the future is.

Other stocks mentioned: ADMA, AZN, BNTX, CERS, PFE, SONN
8 months ago - InvestorPlace

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use of investi...

Other stocks mentioned: ADMA, CERS, GRFS, KMDA, SONN, THMO, TTOO
8 months ago - Benzinga

The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients as part of the agency’s o...

Other stocks mentioned: KMDA, SONN
8 months ago - Benzinga

Liminal BioSciences: Under New Management And Chasing Ryplazim Approval

8 months ago - Seeking Alpha

LAVAL, QC, and CAMBRIDGE, England, Aug. 6, 2020 /PRNewswire/ - Liminal BioSciences Inc.

9 months ago - PRNewsWire

Plasma stocks were trading higher Friday after President Donald Trump encouraged Americans who have recovered from COVID-19 to donate their convalescent blood plasma as a treatment for the virus.

Other stocks mentioned: BURG, KMDA
9 months ago - Benzinga

LAVAL, QC and CAMBRIDGE, England, July 2, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, to...

10 months ago - PRNewsWire

LAVAL, QC and CAMBRIDGE, England, June 30, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, t...

10 months ago - PRNewsWire

LAVAL, QC and CAMBRIDGE, England, June 30, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, t...

10 months ago - PRNewsWire

LAVAL, QC and CAMBRIDGE, United Kingdom, June 11, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical com...

11 months ago - PRNewsWire

LAVAL, QC, and CAMBRIDGE, United Kingdom, May 28, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical com...

11 months ago - PRNewsWire

About LMNL

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel small molecule drug candidates for the treatment of patients suffering from respiratory fibrotic diseases and other fibrotic or inflammatory diseases that have high unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma-Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050), which is in Phase 1 for the treatment of i... [Read more...]

Industry
Biotechnology
CEO
Kenneth Galbraith
Employees
251
Stock Exchange
NASDAQ
Ticker Symbol
LMNL
Full Company Profile

Financial Performance

In 2020, LMNL's revenue was 3.32 million, a decrease of -32.36% compared to the previous year's 4.90 million. Losses were -119.59 million, -42.45% less than in 2019.

Financial numbers in millions CAD.
Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for LMNL stock is "Buy." The 12-month stock price forecast is 10.06, which is an increase of 142.41% from the latest price.

Price Target
$10.06
(142.41% upside)
Analyst Consensus: Buy